<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7808616</journal-id>
<journal-id journal-id-type="pubmed-jr-id">7840</journal-id>
<journal-id journal-id-type="nlm-ta">Trends Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Trends Neurosci.</journal-id>
<journal-title-group>
<journal-title>Trends in neurosciences</journal-title>
</journal-title-group>
<issn pub-type="ppub">0166-2236</issn>
<issn pub-type="epub">1878-108X</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29405930</article-id>
<article-id pub-id-type="pmc">5909705</article-id>
<article-id pub-id-type="doi">10.1016/j.tins.2017.11.005</article-id>
<article-id pub-id-type="manuscript">NIHMS929806</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>MeCP2 as an activator of gene expression</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Horvath</surname>
<given-names>Patricia M.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Monteggia</surname>
<given-names>Lisa M.</given-names>
</name>
</contrib>
<aff id="A1">Department of Neuroscience, the University of Texas Southwestern Medical Center, Dallas, TX 75390-9111, USA</aff>
</contrib-group>
<author-notes>
<corresp id="FN1">Correspondence: Lisa M. Monteggia, Department of Neuroscience, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9111, Tel 214-648-5548, <email>lisa.monteggia@utsouthwestern.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>11</day>
<month>1</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>2</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>2</month>
<year>2019</year>
</pub-date>
<volume>41</volume>
<issue>2</issue>
<fpage>72</fpage>
<lpage>74</lpage>
<!--elocation-id from pubmed: 10.1016/j.tins.2017.11.005-->
<abstract>
<p id="P1">Rett Syndrome is a neurodevelopmental disorder that primarily affects females and is caused by mutations in the methyl-CpG-binding-protein 2 (MeCP2) gene. Initially, MeCP2 had been shown to be a repressor of gene transcription. In their 2008 paper, Chahrour and colleagues (DOI: 10.1126/science.1153252) reported that MeCP2 could also function as a transcriptional activator.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>